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Abstract
Thrombosis is a recognised complication of inflammatory bowel disease (IBD), in particular venous
thrombosis. Arterial thrombosis, especially stroke is rare. There is a paucity of information
regarding stroke in IBD and its management. The authors describe two cases of stroke in patients
with IBD during periods of increased disease activity. The literature regarding this devastating
complication and the procoagulant state that exists in IBD are reviewed.
Background
Thrombosis is a well-recognised complication of inflam-
matory bowel disease (IBD) and is an important cause of
morbidity and mortality. The commonest are deep vein
thrombosis and pulmonary emboli [1]. Arterial thrombo-
sis, in particular stroke, is rare in IBD. No guidelines are
available at present to help manage this severe complica-
tion. The authors describe two cases of stroke in patients
with ulcerative colitis (UC).
Patient 1
A 55 year old, non-smoker, Caucasian man presented to
the emergency room with left sided hemiparesis. The
patient also had bloody diarrhoea (12 times a day). A
diagnosis of ulcerative colitis had been made five years
previously and the patient had been maintained on
mesalazine only. The patient had been evaluated in the
out-patient department three days earlier with an exacer-
bation of his UC and was started on prednisolone 40 mg
daily only. There was no history of vascular disease. On
examination the patient was normotensive (blood pres-
sure 111/80 mmHg) and afebrile. Cardiovascular exami-
nation revealed normal heart sounds, and no carotid
bruits. Abdominal examination revealed tenderness in the
left iliac fossa and reduced bowel sounds. A dense left
sided hemiplegia was noted. Blood tests showed a raised
white cell count of 11.5 × 109/L (NR 4–11) and C-reactive
protein (CRP) of 29.6 mg/L (NR 0–5) and a thrombocy-
tosis of 566 × 109/L (NR 150–400). Fasting cholesterol of
3.3 mmol/L (NR 1.3–5.2) and blood glucose of 3.3
mmol/L (NR 3.3–5.8) were both normal. Stool cultures
were negative. An electrocardiogram demonstrated nor-
mal sinus rhythm. No evidence of cardiomegaly was
noted on a chest radiograph. Trans-thoracic echocardio-
gram and carotid dopplers were normal. Computed tom-
ography (Figure 1) of the brain confirmed an ischaemic
infarct in the right parietal lobe.
Flexible sigmoidoscopy demonstrated an inflamed granu-
lar mucosa with loss of the vascular pattern to the proxi-
mal sigmoid colon. He was commenced on intravenous
hydrocortisone (100 mg QDS) and subcutaneous low
molecular weight heparin (LMWH). Total parenteral
nutrition was also commenced because of the likelihood
of poor enteral absorption. After 14 days of treatment
with hydrocortisone he underwent a total colectomy
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because of poor symptom control and worsening abdom-
inal pain. Postoperative recovery was unremarkable. A
thrombophilia screen (anti-thrombin, protein C and S,
factor V leiden) was negative Twelve months post surgery
the patient is mobilising independently with only mild
weakness of the left upper limb.
Patient 2
A 24 year old Caucasian woman presented to the emer-
gency room with a left sided headache, confusion and
increased bowel frequency (8 times per day). UC had
been diagnosed six months earlier at colonoscopy and
subsequently treated with mesalazine 800 mg BD and
prednisolone 10 mg OD. On examination the patient was
afebrile and normotensive (BP 119/80 mmHg). A global
aphasia was noted with no other neurological deficits.
Blood tests revealed a raised white cell count of 20.1 ×
109/L and CRP at 185 mg/L, and a thrombocytosis of 641
× 109/L. Trans thoracic echocardiogram and carotid dop-
plers were normal. CT of the brain demonstrated an
ischaemic infarct of the left middle cerebral artery terri-
tory. A thrombophilia screen was negative. The patient
was managed conservatively and made an uneventful
recovery with no residual neurological deficit but subse-
quently developed epilepsy. Her colitis has remained well
controlled with azathioprine.
Discussion
We describe two case of stroke in patients with known UC.
Neither patient had any risk factors for cerebrovascular
disease. One patient required a subtotal colectomy for
failed medical treatment whilst the other patient made a
full recovery and was spared surgery but developed epi-
lepsy secondary to her stroke.
Deep vein thrombosis with or without pulmonary embo-
lism remains the most common vascular event complicat-
ing inflammatory bowel disease. Thrombotic events
involving the central nervous system are unusual. Cases of
cerebral venous sinus thrombosis in IBD are well
described [2,3]. Arterial thromboembolic complications
occur less frequently [4] and the majority of cases seem to
occur post surgery [5]. In a study of 7199 patients, only 7
patients with cerebrovascular disease were identified [6].
A review of the literature shows scattered case reports of
arterial strokes in IBD [7-9]. Patients with ulcerative colitis
appear to be more commonly affected than patients with
Crohn's Disease [7]. Men and women are equally affected.
Vitamin B6 deficiency leading to an acquired state of
hyper-homocysteinaemia has also been described as a risk
factor for stroke in IBD [7]. Active disease was also associ-
ated with the occurrence of stroke, but cases have been
described during remission [4]. Pan-colonic disease has
also been suggested as a risk factor for stroke. Significant
morbidity is associated with arterial complications [10].
An increased risk of thrombosis is recognised in patients
with IBD. The incidence of "thrombo-embolic (TE)" com-
plications ranges between 1–8% [11]. The increased risk
of TE complications appears to be unique to IBD when
compared to other inflammatory conditions. Mieshler et
al [12] demonstrated that IBD patients have a 3.6 fold
higher risk of thromboembolism compared with controls.
An increased risk was not seen in patients with coeliac dis-
ease or rheumatoid arthritis. The majority of TE cases
(60%) in patients with IBD occurred during periods of
increased disease activity or in the presence of gastrointes-
tinal complications such as fistulae and abscesses [12].
All components of the coagulation cascade are thought to
be involved in the pathogenesis of IBD [13]. This is the
basis for the use of heparin as a treatment, and also
accounts for the decreased incidence of IBD in patients
with von Willenbrands disease and haemophilia [5]. A
single cause for the hypercoaguable state that clearly exists
in IBD has not been established. An increased frequency
of Factor V Leiden, antithrombin deficiency and the pro-
thrombin (G20210A) gene mutation have not been con-
sistently identified [1]. Protein C and S levels have also
been shown to be no different to controls [14]. Hyperho-
mocysteinaemia is associated with an increased risk of
thrombosis. Homocysteine is generated via the metabo-
lism of methionine and requires vitamins B6, B12 and
folate. A point mutation (C677T) in the methyleneterahy-
drofolate reductase (MTHFR) gene can lead to increased
serum levels. An increased incidence of the point muta-
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tion in the MTHFR in IBD patients with TE complications
has not been established [1].
In the two cases described, both patients had evidence of
active disease. Inflammation during episodes of increased
disease activity is a potent prothrombotic stimulus due to
fibrinolysis inhibition. Increased levels of pro-inflamma-
tory cytokines (TNF and IL-6) and increased production
of soluble CD40 ligand from activated platelets [15,16]
are also thought to play an important role. Studies have
also examined the role played by platelet-leukocyte aggre-
gates (PLA) which are increased in patients with IBD,
compared with healthy and inflammatory control sub-
jects [17,18]. PLAs cause microinfarction and exacerbate
thrombus formation by enhancing the production of tis-
sue factor. Conventional risk factors for thrombosis such
as immobility, dehydration, sepsis and surgery should not
be forgotten.
Consequences of stroke in young patients can be devastat-
ing and even more complicated in the setting of active
IBD. Conventional CT or magnetic resonance imaging
should be performed to identify the anatomical distribu-
tion and the extent of the area affected. No guidelines are
available for the treatment of stroke in IBD. The only evi-
dence appears to be anecdotal, probably due to the pau-
city of cases. Treatment should involve the management
of the underlying bowel disease and prevention or correc-
tion of acquired risk factors leading to the TE event. Novo-
tony et al [10], proposed that all UC patients with an
arterial TE event should undergo a colectomy due to the
likelihood of pan-colonic disease and a poorer long term
prognosis.
Prophylactic doses of LMWH are widely used in patients
with IBD with increased disease activity, evidence of gas-
trointestinal complications, and during surgery or epi-
sodes of sepsis during hospital admissions. This is
recommended by the British Society of Gastroenterology
[19]. Anticoagulation, to prevent further thrombotic epi-
sodes, is a controversial because of the increased risk of
intracerebral and GI bleeding, although patients have
been successfully anticoagulated without bleeding com-
plications [20]. Oral, colonic release, LMWH has now
been used in the treatment of mild to moderate UC [21],
and could represent a future therapeutic avenue. We sug-
gest that all cases of stroke in IBD patients should be
treated as in the general population with aspirin and mod-
ification of atherosclerotic risk factors. We do not advo-
cate the need for total colectomy in the occurrence of an
arterial TE event.
It is not uncommon for patients to present with de novo
IBD with extra-intestinal manifestations which include
vascular events. Clinical awareness of stroke as a compli-
cation of IBD is low. Guidelines are required to help guide
physicians in the management of stroke in IBD. Investiga-
tions for thrombophilia should be reserved for those
patients with atypical or recurrent thromboses or in those
with a strong family history. Further research is needed to
help establish the cause of the hypercoaguable state in
IBD.
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